Dasatinib + Quercetin Frailty Trial: Physical Function Outcomes
Expert Summary
The Justice et al. (2019) D+Q frailty trial randomized 29 individuals ≥70 years with walking limitations (physical frailty) to receive D+Q (dasatinib 100 mg + quercetin 1,000 mg × 3 days over 3 weeks) or placebo. The D+Q group showed significant improvements in 400m gait speed (primary endpoint, p=0.0001), 5x chair stand time (p=0.018), and SF-36 physical function domain (p=0.036).
Key Facts
Primary endpoint — gait speed: 400m walk time improved significantly in the D+Q group (-13% vs +2% in placebo). Gait speed is a strong predictor of mortality in older adults — even small improvements have clinically meaningful implications.
5x Chair stand: Rising from a chair without using hands requires lower limb strength and coordination. D+Q improved this measure significantly, suggesting improved neuromuscular function beyond simple anti-inflammatory effects.
SF-36 physical function: Patient-reported physical function improved in D+Q group. This is a validated quality-of-life measure capturing daily activities. Placebo group showed no improvement.
Biomarker confirmation: Post-treatment p16 mRNA in skin: reduced -29%. SA-β-Gal in adipose tissue: reduced. These confirm that the functional improvements coincide with senescent cell clearance — supporting causality rather than placebo effect.
Duration of effect: Follow-up at 12 weeks showed maintained functional improvements in D+Q group vs baseline. This suggests senolytic treatment benefits persist well beyond the 3-week treatment window.
Safety: No serious adverse events in the frailty trial. Mild fatigue and headache were reported by some D+Q participants. One participant had transient platelet count reduction (grade 1) that normalized without intervention.
Frequently Asked Questions
Who qualifies as physically frail?
Fried Frailty Criteria include ≥3 of: unintentional weight loss, exhaustion, low physical activity, slow gait speed (<0.8 m/sec), and weak grip strength. Pre-frailty (1–2 criteria) is a target for preventive intervention.
Should older adults take senolytics to prevent frailty?
The frailty trial provides the strongest functional outcome evidence for D+Q. For prevention (before frailty develops), natural senolytics (fisetin, quercetin) represent a lower-risk starting point. Those already frail may benefit from physician-supervised D+Q.
How does D+Q compare to exercise for frailty prevention?
Exercise is the gold standard for frailty prevention with the broadest evidence base. D+Q addresses the underlying cellular mechanism (senescent cell accumulation) that exercise cannot fully compensate for in aged individuals. Combining senolytics with a structured exercise program is the emerging best-practice protocol.
Get the free Longevity Supplement Starter Guide
Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.
Scientific References
Justice JN et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine. 2019. PMID: 30616998
Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130